Rafael Holdings Inc

NYSE:RFLUnited States

Nov 6, 2024

Show headlines and story abstract

• *DJ Rafael Holdings 4Q Rev $165,000 >RFL, from 7:14PM ET on Wednesday Nov 06, 2024 by Dow Jones

  7:14PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: RFL

• Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results, from 7:14PM ET on Wednesday Nov 06, 2024 by Dow Jones

  7:14PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: RFL, CYTH
  Due to related parties 733 26 Installment note payable 1,700 -- ---------- ---------- Total current liabilities 7,514 2,145 Accrued expenses, noncurrent 2,982 -- Convertible notes payable, noncurrent 73 -- Other liabilities 5 55 ---------- ---------- TOTAL LIABILITIES 10,574 2,200 COMMITMENTS AND CONTINGENCIES EQUITY Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2024 and July 31, 2023 8 8 Class B common stock, $0.01 par value; 200,000,000 shares authorized, 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024, and 23,635,709 shares issued and 23,490,527 shares outstanding as of July 31, 2023 238 236 Additional paid-in capital 280,048 264,010 Accumulated deficit (201,743) (167,333) Treasury stock, at cost; 101,487 and 0 Class B shares as of July 31, 2024 and July 31, 2023, respectively (168) -- Accumulated other comprehensive income (loss) related to unrealized income on available-for-sale securities 111 (353) Accumulated other comprehensive income related to foreign currency translation adjustment 3,691 3,725 ---------- ---------- Total equity attributable to Rafael Holdings, Inc. 82,185 100,293 Noncontrolling interests 4,073 (3,664) ---------- ---------- TOTAL EQUITY 86,258 96,629 ---------- ---------- TOTAL LIABILITIES AND EQUITY $ 96,832 $ 98,829 ========== ========== RAFAEL HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (in thousands, except share and per share data) Three Months Ended July 31, Year Ended July 31, -------------------------- ---------------------------- 2024 2023 2024 2023 ------------ ------------ ------------ -------------- Revenues $ 165 $ 68 $ 637 $ 279 Cost of infusion Technology revenue 69 - 154 - G&A Expenses 2,330 1,395 8,854 8,932 R&D Expenses 1,543 1,266 4,170 6,312 In-process research and development expense - 0 89,861 - Depreciation and amortization 68 18 225 78 ---------- Operating Loss (3,845) (2,611) (102,627) (15,043) Interest income 606 - 2,383 3,253 Impairment of investments - Other Pharmaceuticals - 17 - (334) Loss on initial investment in Day Three upon acquisition - - (1,633) - Realized gain on available-for-sale securities 251 - 1,772 154 Realized gain (loss) on investment in equity securities - - (46) 309 Unrealized gain on investment in equity securities - - - 33 Realized gain on investment - Cyclo - - 424 - Unrealized gain on investment - Cyclo (3,162) 2,663 37 2,663 Unrealized gain on convertible notes receivable, due from Cyclo 1,191 - 1,191 - Unrealized (loss) gain on investment - Hedge Funds 181 100 63 220 Recovery of receivables from Cornerstone - - 31,305 - Interest expense (163) - (248) - Other income - 1,294 118 - Income (loss) before incomes taxes from continuing operations (4,941) 1,463 (67,261) (8,745) Benefit from taxes 87 (4) 2,680 255 Equity in loss of Day Three - (203) (422) (203) Consolidated net loss from continuing operations (4,854) 1,256 (65,003) (8,693) Discontinued Operations ------------------- Loss from discontinued operations related to 520 Property (65) - (306) Gain on disposal of 520 Property 0 - 6,784 Income from discontinued operations - (65) - 6,478 Consolidated net loss (4,854) 1,191 (65,003) (2,215) Net loss attributable to noncontrolling interests (386) (28) (30,593) (339) Net loss attributable to Rafael Holdings, Inc. $ (4,468) $ 1,163 $ (34,410) $ (1,876) ========== ========== ========== ========== Continuing operations earnings (loss) per share ------------------- Net loss from continuing operations $ (4,854) $ 1,256 $ (65,003) $ (8,693) Net loss attributable to noncontrolling interests (386) -28 (30,593) (339) Numerator for loss per share from continuing operations $ (4,468) $ 1,284 $ (34,410) $ (8,354) ========== ========== ========== ========== Discontinued operations earnings income per share ------------------- Numerator for income from discontinued operations $ - $ (65) $ - $ 6,478 ========== ========== ========== ========== Earnings (loss) per share - Basic and Diluted ------------------- Continuing operations $ (0.19) $ 0.06 $ (1.45) $ (0.36) Discontinued operations - - - 0.28 Total basic earnings (loss) per common share $ (0.19) $ 0.06 $ (1.45) $ (0.08) ========== ========== ========== ========== Weighted average number of shares used in calculation of earnings (loss) per share - basic and diluted 23,916,839 22,263,211 23,745,516 23,263,211